To shed light on the potential clinical implications of the autocrine induction of HRG in lapatinib-resistant HER2+ breast cancer cells, we analyzed the relation between HRG gene expression and clinical outcome in women with HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.